NASDAQ: ACHV
Achieve Life Sciences Inc Stock Forecast, Predictions & Price Target

Analyst price target for ACHV

Based on 1 analyst offering 12 month price targets for Achieve Life Sciences Inc

Min Forecast
$12.00+302.68%
Avg Forecast
$12.00+302.68%
Max Forecast
$12.00+302.68%

Should I buy or sell ACHV stock?

Based on 1 analyst offering ratings for Achieve Life Sciences Inc.

Buy
Strong Buy
0 analysts 0%
Buy
1 analysts 100%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although ACHV's forecast from analysts indicates a "Buy", our proven Zen Rating quant model rates ACHV as a "Sell". Stocks with a Zen Rating of Sell have had an average return of -4.50% per year. Learn More

Be the first to know when Wall Street analysts revise their ACHV stock forecasts and price targets.

ACHV stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-08-21

1 of 1

Forecast return on equity

Is ACHV forecast to generate an efficient return?

Company
560.14%
Industry
122.36%
Market
-50.04%
ACHV's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is ACHV forecast to generate an efficient return on assets?

Company
210.46%
Industry
45.58%
ACHV is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

ACHV earnings per share forecast

What is ACHV's earnings per share in the next 3 years based on estimates from 3 analysts?

Avg 1 year Forecast
-$1.16
Avg 2 year Forecast
-$1.05
Avg 3 year Forecast
$0.23

ACHV revenue forecast

What is ACHV's revenue in the next 3 years based on estimates from 3 analysts?

Avg 1 year Forecast
$17.7M
Avg 2 year Forecast
$96.5M
Avg 3 year Forecast
$200.5M

ACHV vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
ACHV$2.98$12.00+302.68%Buy
ADAG$2.19$7.00+219.63%Buy
PLRX$1.69$3.92+131.78%Hold
HLVX$2.08$2.00-3.85%Hold
IVVD$0.87$3.67+321.01%Strong Buy

Achieve Life Sciences Stock Forecast FAQ

Is Achieve Life Sciences Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: ACHV) stock is to Buy ACHV stock.

Out of 1 analyst, 0 (0%) are recommending ACHV as a Strong Buy, 1 (100%) are recommending ACHV as a Buy, 0 (0%) are recommending ACHV as a Hold, 0 (0%) are recommending ACHV as a Sell, and 0 (0%) are recommending ACHV as a Strong Sell.

If you're new to stock investing, here's how to buy Achieve Life Sciences stock.

What is ACHV's earnings growth forecast for 2025-2027?

(NASDAQ: ACHV) Achieve Life Sciences's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 5.3%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 14.93%.

Achieve Life Sciences's earnings in 2025 is -$46,160,000.On average, 3 Wall Street analysts forecast ACHV's earnings for 2025 to be -$40,234,684, with the lowest ACHV earnings forecast at -$41,622,086, and the highest ACHV earnings forecast at -$39,194,131. On average, 3 Wall Street analysts forecast ACHV's earnings for 2026 to be -$36,419,326, with the lowest ACHV earnings forecast at -$39,887,833, and the highest ACHV earnings forecast at -$32,257,117.

In 2027, ACHV is forecast to generate $7,863,106 in earnings, with the lowest earnings forecast at -$8,671,268 and the highest earnings forecast at $23,932,700.

What is ACHV's revenue growth forecast for 2026-2028?

(NASDAQ: ACHV) Achieve Life Sciences's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 82.69%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.57%.

Achieve Life Sciences's revenue in 2025 is $0.On average, 3 Wall Street analysts forecast ACHV's revenue for 2026 to be $613,925,774, with the lowest ACHV revenue forecast at $520,276,080, and the highest ACHV revenue forecast at $697,169,947. On average, 3 Wall Street analysts forecast ACHV's revenue for 2027 to be $3,348,254,055, with the lowest ACHV revenue forecast at $3,121,656,480, and the highest ACHV revenue forecast at $3,593,373,459.

In 2028, ACHV is forecast to generate $6,954,356,936 in revenue, with the lowest revenue forecast at $5,931,147,312 and the highest revenue forecast at $7,977,566,560.

What is ACHV's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: ACHV) forecast ROA is 210.46%, which is higher than the forecast US Biotechnology industry average of 45.58%.

What is ACHV's Price Target?

According to 1 Wall Street analyst that have issued a 1 year ACHV price target, the average ACHV price target is $12.00, with the highest ACHV stock price forecast at $12.00 and the lowest ACHV stock price forecast at $12.00.

The Wall Street analyst predicted that Achieve Life Sciences's share price could reach $12.00 by Aug 21, 2026. The average Achieve Life Sciences stock price prediction forecasts a potential upside of 302.68% from the current ACHV share price of $2.98.

What is ACHV's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: ACHV) Achieve Life Sciences's current Earnings Per Share (EPS) is -$1.34. On average, analysts forecast that ACHV's EPS will be -$1.16 for 2025, with the lowest EPS forecast at -$1.20, and the highest EPS forecast at -$1.13. On average, analysts forecast that ACHV's EPS will be -$1.05 for 2026, with the lowest EPS forecast at -$1.15, and the highest EPS forecast at -$0.93. In 2027, ACHV's EPS is forecast to hit $0.23 (min: -$0.25, max: $0.69).

What is ACHV's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: ACHV) forecast ROE is 560.14%, which is considered strong.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.